PARIS, FRANCE: Sanofi, a global biopharmaceutical company, announced today the appointment of three new members to its Executive Committee and the departure of one of its senior leaders.

Houman Ashrafian, a renowned scientist and investor, will join Sanofi as Head of Research & Development, starting September 11th, 2023. He will be responsible for advancing Sanofi’s pipeline of innovative medicines and vaccines, and leading its R&D transformation.

Madeleine Roach, a seasoned business executive, will take on the newly created role of Head of Business Operations, effective October 1st, 2023. She will oversee the centralization and optimization of business services across the company, with a focus on driving efficiency and productivity.

Emmanuel Frenehard, a digital and technology expert, will assume the position of Chief Digital Officer, effective immediately. He will lead Sanofi’s digital transformation and data strategy, and support its goal to become the first biopharma company powered by artificial intelligence at scale.

Bill Sibold, Head of the Specialty Care GBU, will leave Sanofi to pursue an external opportunity. Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.

All four executives will report to Sanofi’s CEO, Paul Hudson, and will be based in Paris, France or Cambridge, US.

Paul Hudson commented on the changes: “These new appointments bring three highly qualified global leaders with new insights and world-class expertise in their field. I am confident in their capacity to inspire our people, execute and deliver on our strategy and support our ambition to be an innovative, inclusive and scientifically driven leader. On the science front, we have a bold strategy of first or best-in-class medicines and vaccines to fuel the growth of our company for the years to come. With Houman Ashrafian’s leadership and deep understanding of science, we aspire to make our R&D transformation sustainable. This is what we were aiming for when we laid out our strategy in 2019. With 5 positive read-outs in the first six months of 2023 only, including Dupixent in COPD, our commitment to Sanofi’s scientifically-driven roadmap couldn’t be any stronger”.